Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Recurrent, refractory, or metastatic disease after ≥ 1 prior first-line regimen (chemotherapy or radiotherapy) * Documented EGFR-positive disease (any expression level) by immunohistochemistry (IHC) (may be based on archival sample) * Measurable or evaluable disease by radiograph, CT scan, MRI, and/or physical exam * Appropriate slides of the primary lesion must be available for review of IHC staining assessment by a central pathology team * No clinical evidence of active brain metastases * Patients with brain metastases are eligible provide they have received definitive radiotherapy or chemotherapy and/or have undergone surgical resection for brain metastases * No prior hematological malignancy PATIENT CHARACTERISTICS: * Karnofsky performance status (PS) 60-100% OR ECOG PS 0-2 * Life expectancy ≥ 3 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Granulocytes ≥ 1,000/mm\^3 * Platelet count ≥ 50,000/mm\^3 * Hemoglobin ≥ 8 g/dL * BUN ≤ 2.0 times normal * Serum creatinine ≤ 2.0 mg/dL * Bilirubin ≤ 1.5 times normal * SGOT ≤ 1.5 times normal (with or without liver metastases) * Hepatitis B surface antigen and HIV negative * LVEF ≥ 45 % at rest (by MUGA) * No evidence of depressed left ventricular function * FEV\_1, DLCO, and FVC ≥ 50% of the predicted value * No other malignancy, except for the following: * History of curatively treated in situ squamous cell carcinoma or basal cell carcinoma of the skin * History of other curatively treated malignancy (except those with a hematologic origin) for which the patient has remained in complete remission \> 5 years after completing therapy (as documented by history, physical exams, tumor markers, and radiology scanning) * No serious medical or psychiatric illness that would preclude giving informed consent or receiving intensive treatment * No recent myocardial infarction (within the past year) * No current angina/coronary symptoms requiring medications * No clinical evidence of congestive heart failure requiring medical management (irrespective of MUGA results) * No systolic blood pressure (BP) ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg * Patients with elevated BP must have it controlled by anti-hypertensive medications for at least 7 days prior to the first infusion PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 4 weeks since prior chemotherapy or radiotherapy * At least 4 weeks since prior cetuximab or small molecule EGFR-inhibitors including, but not limited to, gefitinib or erlotinib hydrochloride * No concurrent radiotherapy * No concurrent steroids except for treatment of adrenal failure, septic shock, or pulmonary toxicity or hormones for non-disease-related conditions (e.g., insulin for diabetes)